Krasnodembskaya’s research group works with Mesenchymal Stem Cells (MSC) with the  particular focus  on the MSC based   cell therapy for Acute Respiratory Distress Syndrome (ARDS). ARDS constitutes a  spectrum of severe acute respiratory failure and is leading cause of morbidity and mortality in critically ill. Our central goal is to understand how MSC work in the context of the injury microenvironment, how MSC modulate reparative capacities of the host cells and if we can enhance MSC therapeutic potential. We hope that this research will allow to develop better cell therapies as well as to  identify new therapeutic targets for ARDS and sepsis. The current research projects are investigating effects of MSC on pulmonary macrophage polarisation, MSC modulation of distal lung endothelial and epithelial cell functions  and more recently we became interested in therapeutic potential of MSC-derived extracellular vesicles as a potential cell-free therapy.